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Abstract
Goals of work Empirical antibiotic therapy usually started
in patients who are neutropenic following treatment with
cytostatic chemotherapy for a haematological malignancy
as soon as fever develops to forestall fulminant sepsis.
Hence, accurate and timely detection of fever is crucial to
the successful management of infectious complications in
these patients. We report an investigation of the feasibility
and validity of continuous non-invasive body temperature
measurement.
Patients and methods The feasibility of non-invasive
continuous measurement of the skin temperature was
investigated using the Propaq® device in a cohort of 33
patients receiving an allogeneic HSCT who were all at risk
of developing a febrile episode. Non-invasive continuous
measurement of the skin temperature (CST) was compared
with a standard episodic axillary temperature measurement
(EAT) five times daily using a Terumo® device. The study
period entailed monitoring during the 10 or 12 days that
profound neutropenia was expected to be present.
Main results Measuring the skin temperature continuously
and accurately by using the Propaq® was feasible. The CST
correlated well with the EAT measurements (Pearson r=
0.782). Compared to EAT, the start of empirical therapy
could be started 2.5 h earlier when relying on continuous
measurements than was possible with EAT.
Conclusion Continuous skin temperature measurements are
feasible and valid compared to the conventional tempera-
ture measurement and may improve the management of
infections by earlier detection of fever in neutropenic
patients.
Keywords Cancer.Infection.Promptantibiotictherapy.
Neutropenia.Bodytemperature
Introduction
Approximately 90% of cycles of intensive chemotherapy
used to treat acute leukaemia are complicated by prolonged
and profound neutropenia that is usually accompanied by
fever and infections [11]. Neutropenic patients who are
febrile are at high risk for developing sepsis, which often
necessitates acute admission to the Intensive Care Unit
(ICU) and is associated with a high mortality [3]. Fever is
usually the most obvious sign of a systemic inflammatory
response [5], so measuring the body temperature is one of
the most important nursing tasks. Instituting empirical
broad-spectrum antimicrobial therapy promptly at the first
sign of fever has been shown crucial to patient survival and
remains the cornerstone of infection management [2, 8, 13].
Mortality associated with fever and neutropenia has
dramatically decreased over the last three decades and is,
in no small measure, the result of general adherence to the
concept of giving empirical therapy with broad-spectrum
antibiotics promptly at the onset of fever [7]. Needless to
say this approach hinges upon the early detection fever by
measuring the body temperature.
A variety of methods are used to measure body
temperature, involving different sites, instruments and
techniques. The core temperature is best measured in the
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e-mail: m.vanvliet@cisvpl.umcn.nlpulmonary artery using a Swan-Ganz catheter [4, 15], but
this is impossible to employ on a haematology ward in
daily clinical practice. Mercury thermometers are now
obsolete and have been replaced by electronic devices.
These thermometers accurately predict temperature and can
be adapted for use at different body sites to measure
temperature orally, axillary, tympanically or rectally [14].
However, the choice of sites for adults on a haematology
ward is limited. Temperature is most often measured orally
although oral mucositis results in erroneous measurements
[1]. Rectal measurement during thrombocytopenia is too
dangerous because of the risk of rectal bleeding. There are
convincing data to show that tympanic temperature mea-
surement is reliable, but the results are more variable than
found with rectal or oral readings [12]. For these reasons,
we have continued to measure the axillary temperature for
our adult population [10].
For continuous measurements, a temperature sensor
connected to the Welch-Allyn® Propaq monitor was used.
This device is able to measure temperature continuously. In
this audit, 24 h non-invasive measurement of skin temper-
ature was explored. The goals were:
1. To assess the feasibility of continuously monitoring the
skin temperature of adults admitted to the haematology
ward for an HSCT.
2. To assess the validity of the data by calculating the
correlation between the values measured by the
continuous device and the axillary measurements.
Patients and methods
Patient population
The audit was carried out on the haematology ward of the
Radboud University Nijmegen Medical Centre where 33
patients admitted to receive an HLA compatible allogeneic
haematopoietic stem cell transplant (HSCT) from a sibling
or a voluntary unrelated donor, consented verbally to
participate. Ethics Committee approval was not required.
Both myeloablative or non-myeloablative conditioning was
used for prepatory regimen. Demographic data of the
patients are shown in Table 1.
Procedure
Participating patients had their body temperature measured
simultaneously by two different instruments. This period
was defined as the first 10 days post-transplant or, in the
case of idarubicin, 2 days before HSCT until 10 days post-
Gender 14 Male
19 Female
Age Mean 48.0 years (range 22-64)
Type of transplant Sibling HSCT (17)
Voluntary Unrelated Donor HSCT (16)
Underlying disease Acute myeloid leukaemia (10)
Myelodysplastic syndrome (5)
Severe aplastic anaemia (4)
Chronic lymphocytic leukaemia (3)
Non-Hodgkin’s lymphoma (4)
Acute lymphocytic leukaemia (3)
Multiple myeloma (1)
Chronic myeloid leukaemia (1)
Myelofibrosis (1)
Acute basophile leukaemia (1)
Conditioning regimen Myeloablative
Idarubicin–cyclophosphamide–total body irradiation (TBI) (9)
ATG–cyclophosphamide–TBI (11)
ATG–cyclophosphamide–fludarabine (4)
Idarubicine–busilvex–cyclophosphamide (1)
Nonmyeloablative
Cyclophosphamide–fludarabine–TBI (2)
Cyclophosphamide–TBI (3)
Cyclophosphamide and fludarabine (2)
Cyclophosphamide–TLI (1)
Table 1 Demographic data
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whilst others were given within a week. Temperature was
scheduled to be registered five times daily at fixed times:
03:00, 08:00, 13:00, 18:00 and 22:00. The maximum
interval between two measurements was 5 h.
Instruments
EAT
We used a Terumo® axillary thermometer, type C202, to
measure axillary temperature. The device was calibrated for
the range of 32.0–42.0°C, in steps of 0.5°, by means of a
warm water bath. The maximum deviation after 90 s was
0.02°, as was internally validated by the technical service
(data not shown). The Terumo thermometer predicts the
axillary temperature after approximately 60 s.
CST
Continuous measurement was achieved by using a temper-
ature sensor connected to the Welch-Allyn® Propaq
monitor. This device measures temperature continuously
preferably in a body cavity that is least exposed to ambient
air. Patients were asked to carry the sensor either in their
groin or axilla, though the former was preferred as it is least
influenced by the patient’s movements.
Supportive care
Empirical therapy was started once when the axillary
temperature as measured by episodic axillary temperature
(EAT) was equal to, or exceeded, 38.5°C. When contin-
uously measured skin temperature (CST) indicated T≥
38.3°C axillary measurement was performed to see if EAT
confirmed this. At the onset of fever, blood was obtained
for cultures, ceftazidime was administered empirically, and
the attending physician was alerted. A blood culture was
considered positive if one or more cultures yielded a
microorganism, except for coagulase-negative staphylo-
cocci, for which two separate positive blood cultures
yielding the same strain were required to be considered to
represent bacteraemia [9].
Audit
Feasibility was tested in the first six patients, and a go/no-go
decision to continue the audit was made. Carrying the device
was found feasible when five of the six patients could bear
the sensor during the day, and the monitor reflected the body
temperature. Patients were interviewed to assess the feasi-
bility ofcarryingatemperature device onthebodyduringthe
day. The validity of the continuous measurements was
assessed by comparing pairs of simultaneously measured
values and calculating the correlation and regression
between them.
Data analysis
Data on the validity of the measurements were collected by
the nurses of the ward. A registration form was specially
developed to record the data. All temperature measurements
were recorded during 10 or 12 days of observation.
Data were imported in SPSS® version 14.0 for data
analysis. Correlation and regression analysis were per-
formed to assess validity of the experimental measure-
ments. The outliers in temperature difference, defined as a
0.5° difference (ΔT) or more between the two simulta-
neously used methods were analysed on possibly con-
founding factors age, BMI and gender.
Results
1. Feasibility
Feasibility was assessed after the first six patients had
been observed, and the decision was made to continue
when five patients had been shown to have no problems
carrying the CST device. A total of 33 patients were
included and 29 completed the observation period success-
fully. Each patient could move around freely as the sensor
was not attached to their body and could easily be
disconnected temporally when desired. During the audit,
one patient was uncomfortable carrying the device during
the day and withdrew from the study for that reason. Three
patients complained about the sensor and considered
abandoning the study but decided to continue. The CST
did not reflect the body temperature in one case as the
patient’s physique did not permit sufficient isolation from
ambient air.
2. Validity of the CST related to the EAT
Regarding the difference in the simultaneously measured
body temperature between the EAT and the CST (ΔT),
1,409 values were valid for evaluation as missing values
were not properly recorded on the registration form. As
shown in Fig. 1, 90% of the differences in measurements
are located in a range of −0.5°C to 0.9°C. The CST
measured both higher and lower temperatures than was
recorded for EAT and frequency, the values of both were
distributed in a Gaussian fashion though EAT was on
average 0.23° higher (Fig. 1).
There was a good correlation between the two methods
(Fig. 2; Pearson correlation of 0.782, p≤0.01). Regression
analysis yielded an R
2 of 0.612 and the intercept and slope
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0.934*x+2.259. For an axillary temperature of 36°C, the mean
deviation of the CST was 0.12°; for an axillary temperature of
40.5°C, the mean deviation of the CST was 0.41°.
ΔT was 0.5 or more in 29.5% of all cases. Per patient, a
ΔT≥0.5 was found in 2% to 69% of the total number of
measurements suggesting that patient characteristics played
a considerable role. Analysis of ‘gender’ and ‘ΔT≥0.5’
showed no significant difference between the groups (p=
0.309), and there was no influence of either BMI (p=0.227)
or age (p=0.614).
In 78% of patients, bacteraemia was detected during the
initial febrile episode during neutropenia justifying the
decision to start broad-spectrum antibiotic treatment.
Although it was not the primary object of the study, we
noted that antibiotics were started over 2.5 h earlier for 12
out of 14 evaluable patients as a result of earlier detection
of fever by continuous measurements.
Discussion
Fever is regarded as the most important means of
identifying an inflammatory process in neutropenic patients,
but there is reason for concern as the reliability of the
common methods of temperature measurement all appears
to have limitations. A high frequency of recording vital
signs should be adopted with in every haematology ward’s
daily practice where early detection of fever can be life-
saving. Surprisingly, no published data were available on
non-invasive continuous body temperature measurement in
oncology patients.
The goals of this audit were to assess feasibility and
validity of continuous skin temperature measurement
(CST). This audit found that CST is feasible in clinical
haematology patients and is valid compared to the
traditional measurements except when a patient is physi-
cally incapable of carrying the sensor where it can remain
sufficiently isolated.
The extreme values observed (ΔT≥0.5) were likely
explained by the malpositioning of either of the instru-
Fig. 2 Scattergram with regres-
sion line on the correlation of
two independent measurements
of body temperature
Fig. 1 Histogram on the difference (EAT minus CST) in simulta-
neously measured temperature by two different methods outliers are
left out)
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0.5 and factors of the human physical composition such as
gender, BMI and age were explored but these did not
explain the findings. Both the standard instructions with the
Terumo (proper placement and drying the axilla previous to
the measurement) and the continuous device (isolation from
outside air is necessary for reliable values) are sensitive to
erroneous measurement. Also, the positioning of the device
could account for this when done by the patients them-
selves. Alternatively this may reflect a common problem,
namely inconsistency in the use of thermometry in daily
practice.
Early detection of fever is a challenge during cycles of
chemotherapy where the start of empirical antibiotic
therapy can be life-saving during neutropenia. All guide-
lines emphasise the immediate start of empirical therapy at
the onset of fever so it makes sense to increase the
frequency of measurements to increase the chance that the
onset of fever is detected promptly. This is not the case
when the temperature is only measured every 4–6 hours,
but reliable continuous measurements allow the onset of
fever to be caught in the act so to speak.
The fact that 78% of the patients actually had bacter-
aemia during the first episode of fever sufficiently justifies
the start of broad-spectrum antibiotic treatment as soon as
fever occurs. Hence, it could be argued that the lack of a
rapid, reliable and continuous means of temperature
monitoring may increase the risk for developing a system-
atic inflammatory response syndrome (SIRS), sepsis, shock
and even death.
Although the concept of fever is familiar to nurse, the
precise definition we should adopt for optimal patient
outcomes is far from clear as a variety of thresholds varying
between 37.5 and 38.5 are employed, and the temperature
is measured in several different ways. For instance, the
2002 IDSA guidelines recommends using a definition of
fever as a single measured oral temperature of ≥38.3 or a
temperature of ≥38.0 for ≥1h[ 6], despite the influence of
oral mucositis on oral thermometry [1]. Clearly, there is still
much to be done.
Conclusion
Continuous temperature measurement makes it possible to
monitor patients intensively during round the clock without
involving extra personnel. Continuous body temperature
measurement is commonly used in the ICU but is alien to
haematology wards. Earlier detection of the onset of fever
and SIRS makes earlier initiation of empirical therapy
possible which might lead to fewer days with fever, reduce
antibiotic usage, the length of stay and mortality and allow
better deployment of nursing staff.
Future directions
Neither CST and EAT are considered to be the Gold
standard for estimating the core temperature. Ideally, a valid
means of continuously measuring temperature needs to be
developed that is more reliably correlated to core temper-
ature. However, it will be a challenge to find a method of
reliably achieving this while being economic and user-
friendly. In the meantime, further research should be done
on a larger group of neutropenic patients exploring the
consequences of earlier detection of fever on outcomes
such as length of stay, costs and amount of antibiotics and
survival.
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